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INTRODUCTION
Mucinous carcinoma (MC) of the breast is a rare histological 
type that is characterized by a large amount of mucin produc-
tion. MC of the breast is defined as having a mucinous compo-
nent of 50% or more [1-3]. The incidence of MC was reported 
to be 1-6% of all primary breast cancers [1-8]. MC usually occurs 
in elderly and the median age at diagnosis is older than 55-60 
years [1,4-6,9-11].
The subgroups of MC, pure-type and mixed-type MC, are 
classified upon the quantification of cellularity [12,13]. The 
“pure” type consists exclusively of tumor tissue with extracel-
lular mucin production, while the “mixed” type is defined by 
the World Health Organization (WHO) as a tumor where 50-
90% of the area is mucinous and also admixing with infiltrating 
ductal epithelial component [14].
Fujii et al. [15] investigated the genomic features of pure-
type MC and found that it does not have the extensive genomic 
alterations typically found in more common variants of breast 
cancer. Moreover, MC exhibited less genetic instability than 
other forms of breast cancer and its molecular pathogenesis 
appeared substantially different from that of the usual breast 
carcinoma. Recently, a study by Lacroix-Triki et al. [3] supported 
these findings and found that MCs were not only a histological 
pattern, but also a molecular entity, distinct from invasive ductal 
carcinoma-not otherwise specified (IDC-NOS).
Nevertheless, because of relative rarity of MC patients, the 
prognostic significance of clinicopathological characteristics is 
not well established and most reported MC series have a low 
number of patients and a limited long-term follow-up. Since 
the incidence of breast cancer is significantly increasing in Korea 
[16,17], the objective of this study was to evaluate the long term 
disease-free survival (DFS) and overall survival (OS) as well as 
the significance of the available clinical and pathological prog-
nostic factors with the goal of using this information to develop 
an adequate treatment guideline.
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Purpose: Mucinous carcinoma (MC) of the breast is a rare histo-
logic type of mammary neoplasm. The objective of this study 
was to evaluate the long-term disease-free survival (DFS) and 
overall survival (OS) of MC. Methods: We conducted a retrospec-
tive analysis of all MC cases reported to a database between 
1994 and 2010. Clinicopathological characteristics and survival 
of 268 MC cases were reviewed and compared with 2,455 inva-
sive ductal carcinoma-not otherwise specified (IDC-NOS) cases. 
Results: The MC cases were of a younger age, involved less lymph 
nodes, lower stage, more expression of hormonal receptors, and 
less HER2 overexpression compared to the IDC-NOS cases. The 
5-year DFS rate for MC was 95.2% compared to 92.0% for IDC-
NOS. The 5-year OS rate for MC was 98.9% compared to 94.9% 
for IDC-NOS. Multivariate analysis using Cox regression revealed 
that the mucinous type was a significant prognostic factor for DFS 
with lower nodal status (N stage) and hormonal therapy. For OS, 
only N stage was the most significant prognostic factor followed 
by adjuvant chemotherapy and adjuvant hormonal therapy. Con-
clusion: MC was shown to be associated with a better DFS than 
IDC-NOS, but it had a similar OS. Nodal status and adjuvant ther-
apy appear to be more significant predictors of prognosis than 
histologic subtype.
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METHODS
Patients were selected from the database of the Breast Cancer 
Center at Samsung Medical Center, Korea between 1994 and 
2010. Of these patients, 268 had been diagnosed with MC. 
These patients were compared to 2,455 patients diagnosed with 
IDC-NOS who were treated during the same period.
Pure-type MC was defined as having a mucinous component 
of more than 90%, using specialized pathologists with extensive 
experience in breast pathology performing a pathologic slide 
review. Among 268 patients, 215 (80.2%) were pure MC and 
53 patients (19.8%) were mixed mucinous-ductal carcinoma.
We reviewed clinicopathologic factors, immunohistochem-
istries of biologic factors such as estrogen receptor (ER), proges-
terone receptor (PR), human epidermal growth factor receptor 
2 (HER2), and treatment modalities (type of operation, use of 
chemotherapy, radiation therapy, and hormone therapy). The 
pathologic tumor stage was assessed according to the 6th Amer-
ican Joint Committee on Cancer (AJCC) Staging System [18]. 
The histological grade was determined according to the Bloom-
Richardson classification. The Allred score was used to measure 
ER or PR positivity, and HER2 was scored as 0-3. Patients with 
an immunohistochemistry (IHC) score of 2+ or gene amplifi-
cation determined by fluorescence in situ hybridization (FISH) 
Table 1. Clinicopathological characteristics and treatment modalities of 
invasive ductal carcinoma (IDC) and mucinous carcinoma (MC)
Characteristics
IDC  
No. (%)
MC  
No. (%) 
p-value
Age (yr)* 47 (21-84) 44 (22-87) <0.001
Family history of breast cancer 1,914 237 0.649
   Yes     179 (9.3)    20 (8.4)
   No    1,735 (90.7)    217 (91.6)
Operation 2,455  268 0.095
   MRM    1,011 (41.2)    125 (46.6)
   BCS    1,444 (58.8)    143 (53.4)
T stage 2,446 267 0.838
   T1    1,359 (55.6)    143 (53.6)
   T2       973 (39.8)    113 (42.3)
   T3       96 (3.9)    10 (3.7)
   T4       18 (0.7)      1 (0.4)
N stage 2,455 268 <0.001
   N0    1,442 (58.7) 217 (81)
   N1       653 (26.6)      36 (13.4)
   N2     241 (9.8)    12 (4.5)
   N3     119 (4.9)      3 (1.1)
Estrogen receptor 2,364 252 <0.001
   Positive    1,552 (65.7)    240 (95.2)
   Negative       812 (34.3)    12 (4.8)
Progesterone receptor 2,363 251 <0.001
   Positive    1,405 (59.5)    215 (85.7)
   Negative       958 (40.5)      36 (14.3)
HER2/neu 2,341 202 <0.001
   HER2 negative    1,760 (75.2)    191 (94.6)
   HER2 positive       581 (24.8)    11 (5.4)
Chemotherapy 2,307 265 <0.001
   Yes    1,948 (84.4)    126 (47.5)
   No       359 (15.6)    139 (52.5)
Radiation therapy 2,253 258 0.062
   Yes 1,577 (70)    166 (64.3)
   No    676 (30)      92 (35.7)
Hormone therapy  1,842 253 <0.001
   Yes    1,140 (61.9)    224 (88.5)
   No       702 (38.1)      29 (11.5)
MRM=modified radical mastectomy; BCS=breast conserving surgery; HER2= 
human epidermal growth factor receptor 2. 
*Mean (range).
Table 2. Clinicopathological characteristics and treatment modalities of 
mucinous carcinoma (MC) by subgroups (pure type and mixed type)  
Characteristics
Pure type
 No. (%)
Mixed type
 No. (%)
p-value
Age (yr)* 44 (22-83) 46 (28-87) 0.386
Family history of breast cancer 188 49
   Yes 17 (9)    3 (6.1) 0.773
   No 171 (91)    46 (93.9)
Operation 215 53 0.188
   MRM      96 (44.7)    29 (54.7)
   BCS    119 (55.3)    24 (45.3)
T stage 214  53  0.26
   T1    119 (55.6)    24 (45.3)
   T2      88 (41.1)    25 (47.2)
   T3      6 (2.8)    4 (7.5)
   T4      1 (0.5) 0 (0)
N stage 215 53 <0.001
   N0    192 (89.3)    25 (47.2)
   N1    18 (8.4)    18 (33.9)
   N2      5 (2.3)      7 (13.2)
   N3     0    3 (5.7)
Estrogen receptor 200 52 1
   Positive 190 (95)    50 (96.2)
  Negative 10 (5)    2 (3.8)
Progesterone receptor 200  51 0.556
   Positive 170 (85)    45 (88.2)
   Negative   30 (15)      6 (11.8)
HER2/neu 158 44 0.708
   HER2 negative    150 (94.9)    41 (93.2)
   HER2 positive      8 (5.1)    3 (6.8)
Chemotherapy 243 52 <0.001
   Yes      87 (40.8) 39 (75)  
   No    156 (59.2) 13 (25)
Radiation therapy 208 50 0.955
   Yes    134 (64.4) 32 (64)  
   No      74 (35.6) 18 (36)
Hormone therapy  202 51 0.059
   Yes    175 (86.6)    49 (96.1)
   No      27 (13.4)    2 (3.9)
MRM=modified radical mastectomy; BCS=breast conserving surgery; HER2= 
human epidermal growth factor receptor 2. 
*Mean (range).310   Soo Youn Bae, et al.
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were considered positive. Time to follow-up is the interval be-
tween the date of operation and the date of the most recently 
identified patient contact or database update. 
Student’s t-tests or Fisher’s exact tests were used to compare 
the clinicopathological characteristics of the MC and IDC 
groups. The Kaplan–Meier method and Cox regression analysis 
were used to determine DFS rates and OS rates. Statistical 
analyses were performed using PASW Statistics 18 (Interna-
tional Business Machines Co., New York, USA).
RESULTS
Clinicopathological characteristics and treatment patterns 
of all patients are shown in Table 1. Median age at diagnosis 
was 44 years for MC patients (range, 22-87 years), and the age 
at diagnosis was much younger in MC patients than in IDC-
NOS patients (median age, 47 years; range, 21-84; p<0.001). 
Tumor size (T stage) was not significantly different from IDC-
NOS. Of the MC patients, 217 (81.0%) had no axillary lymph 
node involvement and MC patients had a lower N stage than 
IDC-NOS patients (p<0.001). Expressions of ER or PR were 
higher in MC (96.0%) than in IDC-NOS (67.7%), and these 
differences were significant (p<0.001). Of the 202 patients 
whose HER2/neu status was available, only 11 (5.4%) showed 
HER2/neu overexpression. MC patients showed a more favor-
able histologic grade than IDC-NOS patients (p<0.001). Less 
chemotherapy and more hormone therapy were applied to MC 
patients, probably because of the favorable features associated 
with higher ER or PR expression and lower histologic grade in 
MC. However, the rates of radiation therapy were not signifi-
cantly different between MC and IDC-NOS patients. 
Clinicopathological characteristics and treatment patterns 
of pure-type MC were similar to those with mixed-type MC 
except for N stage (Table 2). No significant difference in age at 
diagnosis was observed between the pure-type MC and mixed-
type MC (44 vs. 46 years, p=0.368). Pure-type MC was smaller 
in size (median, 2.0 cm; mean, 2.3 cm) than the mixed type 
(median, 2.5 cm; mean, 2.9 cm; p=0.033), although there 
were no significant differences in T stage. Pure-type MC also 
had a more differentiated histologic grade (p<0.001) and lower 
lymph node metastases than mixed-type MC (10.7% vs. 52.8%, 
p<0.001).
The median follow-up duration was 49.7 months for all pa-
tients (range, 0-181 months). For MC patients, the 5-year DFS 
Figure 1. Comparison of disease-free survival (DFS) curves for invasive 
ducal carcinoma (IDC) and mucinous carcinoma.
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Figure 2. Comparison of overall survival (OS) curves for invasive ducal 
carcinoma (IDC) and mucinous carcinoma.  
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
p=0.061
0  60  120  180
1.0
0.8
0.6
0.4
0.2
0.0
IDC
Mucinous
IDC-censored
Mucinous-censored
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
OS
OS
Pure vs. IDC, p=0.025
Mixed vs. IDC, p=0.77
Pure vs. Mixed, p=0.043
0  24  48  72  96  120
1.0
0.8
0.6
0.4
0.2
0.0
IDC
Pure
Mixed
IDC-censored
Pure-censored
Mixed-censoredMucinous Breast Cancer  311
http://dx.doi.org/10.4048/jbc.2011.14.4.308  http://ejbc.kr
rate was 95.2% and in IDC-NOS patients it was 92.0% (Figure 
1). The 5-year OS rates of MC patients was 98.9% and IDC-
NOS patients was 94.9% (Figure 2). The DFS and OS rates 
were not significantly different between MC and IDC-NOS 
(p=0.072 and p=0.061, respectively). Although a significant 
difference in DFS for MC was not observed in the univariate 
analysis by the Kaplan-Meier method, multivariate analysis by 
Cox regression revealed that mucinous type was a significant 
prognostic factor for DFS with lower N stage and hormonal 
therapy (Table 3). According to multivariate analysis for OS, 
nodal status (N stage) was the most significant prognostic factor, 
followed by adjuvant chemotherapy and adjuvant hormonal 
therapy. The mucinous type itself was not associated with an 
improvement in overall survival (Table 3).
Figure 3. Overall survival (OS) curves for invasive ducal carcinoma (IDC) 
and mucinous carcinoma, stratified by stage.
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Figure 4. Overall survival (OS) curves for invasive ducal carcinoma (IDC) 
and mucinous carcinoma, stratified by tumor size (T stage). 
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
OS
T1
p=0.516
0  24  48  72  96  120
1.0
0.8
0.6
0.4
0.2
0.0
IDC
Mucinous
IDC-censored
Mucinous-censored
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
OS
T2
p=0.028
0  24  48  72  96  120
1.0
0.8
0.6
0.4
0.2
0.0
IDC
Mucinous
IDC-censored
Mucinous-censored
C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
OS
T3
0  24  48  72  96  120
1.0
0.8
0.6
0.4
0.2
0.0
p=0.384
IDC
Mucinous
IDC-censored
Mucinous-censored312   Soo Youn Bae, et al.
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2011.14.4.308
The 5-year DFS rates were 96.1% for pure-type MC and 
87.5% for mixed-type MC (Figure 1). Pure-type MC showed 
a better DFS than IDC-NOS (p=0.044), but was not signifi-
cantly different from mixed-type MC (p=0.128). Pure-type 
MC had a better OS than IDC-NOS (p=0.025) and mixed-
type MC (p=0.043). However, the DFS between mixed-type 
MC and IDC-NOS was not significantly different (p=0.848) 
or OS (p=0.77).
In stage-matched analysis for DFS and OS, MC showed a 
better survival than IDC-NOS (Figure 3), but no significant 
differences were observed between the group. This lack of sig-
nificance was probably due to the small sample size and short 
follow-up duration. In T stage-matched analysis for DFS and 
OS, MC showed a better survival than IDC-NOS (Figure 4), 
but only the T2-stage MC group showed significantly better 
OS (p=0.028).
DISCUSSION
MC is a rare histologic type of mammary neoplasm. In the 
West, MC patients usually are postmenopausal women and 
older than IDC-NOS patients [2,5-7,10,11,19]. However, in 
our study, MC patients were younger than IDC-NOS patients. 
This is in agreement with Park’s finding for Korean MC pa-
tients. Park et al. [20] suggested that breast cancer may have     
a younger age of onset in Korean women due to the wide use 
of ultrasonography, or genetic and environmental factors. In 
addition, a cohort effect may exist in younger generations, or 
the apparent increase in incidence may reflect the easy acces-
sibility to breast cancer screening among middle-aged women, 
which is similar to the results reported in a Japanese study [21]. 
However, histological features and survival rates of MC were 
similar between Korean patients and Western patients.
 Axillary nodal involvement in MC patients, although rare, 
seems to worsen the prognosis of breast cancer. A previous 
study found that patients with node-positive MC in the breast 
were significantly more likely to have recurrence and poor prog-
nosis [2,5,7,12,22]. The incidence of axillary metastases ranged 
from 2% to 14% in pure MC [2,8,9,11,23,24] and 45% to 64% 
in mixed MC [2,12,24]. This trend was corroborated in our 
study (10.7% in pure MC and 52.8% in mixed MC). Because 
the status of the axillary lymph nodes, pure MC has a better 
prognosis than mixed MC [7,9,12,23,24]. Although pure-type 
MC has been associated with a better short-term prognosis than 
IDC, previous studies reported identical long-term survival 
curves [1,2,4,25].
Avisar et al. [9] identified certain factors that were associated 
with a higher incidence of axillary nodal disease in MC patients, 
which included younger age, aneuploidy, high nuclear grade, 
and a negative estrogen receptor status. In our study, patients 
with higher T stage and negative estrogen receptor had higher 
nodal metastases.
The prognostic significance of tumor size is an interesting 
issue in MC patients. Di Saverio et al. [1] utilized tumor size 
was an independent prognostic indicator, but it was less signif-
icant than nodal status and age in multivariate analysis of a 
large number of pure-type MC cases. Although some studies 
have not found any correlations between tumor size and the 
incidence of axillary nodal metastases [9,26], others found that 
the incidence of node positivity was directly related to tumor 
size [1,5]. Diab et al. [5] demonstrated that patients with tumor 
size ≤1 cm had a <5% risk of developing lymph node metas-
Table 3. Multivariate analysis of disease-free survival (DFS) and overall survival (OS) of mucinous carcinoma and invasive ductal carcinoma (IDC)
 
DFS OS 
B coeff Wald p-value Exp(B)
95% CI
B coeff Wald p-value Exp(B)
95% CI
 Min  Max  Min  Max
Age at diagnosis -0.016 2.933 0.087 0.984 0.966 1.002 0.012 1.213 0.271 1.013 0.990 1.035
Operation (BCS) 0.335 1.383 0.240 1.398 0.800 2.444 0.131 .194 0.660 1.140 0.636 2.043
CTx -0.354 1.687 0.194 0.702 0.411 1.198 -0.959 6.434 0.011 0.383 0.183 0.804
RTx -0.063 0.045 0.833 0.939 0.522 1.687 0.465 1.733 0.188 1.593 0.797 3.184
HTx -0.730 15.524 0.000 0.482 0.335 0.693 -1.184 24.476 0.000 0.306 0.191 0.489
T stage 1.439 0.696 6.515 0.089
   T1 0.002 0.000 0.991 1.002 0.665 1.510 -0.171 0.421 0.516 0.843 0.503 1.413
   T2 0.491 1.281 0.258 1.634 0.698 3.823 0.813 3.892 0.049 2.256 1.005 5.061
   T3 -0.011 0.000 0.991 0.989 0.132 7.402 -10.435 0.003 0.957 0.000 0.000    2634E
N stage 11.681 0.009 46.905 0.000
   N1 0.079 0.102 0.749 1.082 0.669 1.750 1.219 12.406 0.000 3.383 1.717 6.664
   N2 0.842 7.295 0.007 2.321 1.260 4.274 2.300 36.573 0.000 9.977 4.734 21.027
   N3 1.097 8.658 0.003 2.994 1.442 6.215 2.653 40.235 0.000 14.196 6.254 32.223
Type (IDC) 0.953 4.048 0.044 2.594 1.025 6.567 0.654 1.144 0.285 1.923 0.580 6.376
CI=confidence interval; Min=minimum; Max=maximum; BCS=breast-conserving surgery; CTx=chemotherapy; RTx=radiation therapy; HTx=hormone therapy.Mucinous Breast Cancer  313
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tasis. In our study, MC showed significantly lower rates of nodal 
metastases than IDC-NOS in T1 and T2 stage (p<0.001), but 
no difference was observed in T3 and T4 stages. This may be 
explained by the survival difference with IDC-NOS, especially 
in stage II patients. Although no significant differences in stage 
II patients was observed, this OS difference in stage II patients 
was also seen in previous studies [2,20]. Diab et al. [5] demon-
strated a significantly better DFS for MC versus IDC-NOS, 
even in a subset of patients with node negativity; however, we 
found no significant differences between the two groups in the 
node negative subset.
In Koreans, MC patients were in younger than IDC-NOS 
patients, and showed favorable characteristics including less 
involvement of lymph node, lower stage, more expression of 
hormonal receptors, and less HER2 overexpression. MC was 
shown to be associated with a better DFS than IDC-NOS, but 
it has a similar OS. Nodal status and adjuvant therapy appear 
to be more significant predictors of prognosis than histologic 
type.
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